
|Videos|December 13, 2020
Analysis of an investigational ophthalmic solution for treating presbyopia-related symptoms
Author(s)David Hutton, Alex Delaney-Gesing
Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.
Advertisement
Michael R. Robinson, MD, vice president, Global Therapeutic Area Head, Ophthalmology at Allergan, an AbbVie company, discusses the results from a presentation titled, "Two Phase b Study Results for the Development of a Proprietary Formulation for the Treatment of Presbyopia," presented during the virtual AAO 2020 meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Lumvoa gains US FDA approval for thyroid eye disease with class-first broad label
2
European Dry Eye Society Congress 2026: real-world evidence on Artelac Complete in dry eye disease
3
DEX implant shows benefit across RVO subgroups in real-world retrospective study
4

























